CME: Managing diabetic ketoacidosis--a delicate balance

Article

Diabetic ketoacidosis is one of the most common, and dangerous, complications of both insulin- and noninsulin-dependent diabetes. The patient's life depends on a complex therapeutic juggling act to restore metabolic, acid-base, fluid, and electrolyte balances.

Recent Videos
Stephanie Chao, MD
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Discussion: AAP's opioid for acute pain clinical practice guideline with Jessica Spruit, DNP
Bobbie Monaco, MSN, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
Navepegritide NDA submitted to treat children with achondroplasiaLatest revision | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

Navepegritide NDA submitted to treat children with achondroplasia

Joshua Fitch, Senior Editor
March 31st 2025
Article

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Weekly review: Multiple FDA approvals, expert discussions and more | Image Credit: © Artur - © Artur - stock.adobe.com.

Weekly review: Multiple FDA approvals, expert discussions and more

Joshua Fitch, Senior Editor
March 31st 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
5 pediatric FDA decisions to watch for in Q2 2025Latest revision | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

5 pediatric FDA decisions to watch for in Q2 2025

Morgan Ebert, Managing Editor;Joshua Fitch, Senior Editor
Published: March 28th 2025 | Updated: March 28th 2025
Article

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

Remestemcel-L now available to treat steroid-refractory acute graft-versus-host diseaseLatest revision | Image Credit: © MdBabul - © MdBabul - stock.adobe.com.

Remestemcel-L now available to treat steroid-refractory acute graft-versus-host disease

Joshua Fitch, Senior Editor
March 28th 2025
Article

Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase.

© 2025 MJH Life Sciences

All rights reserved.